GSK-DB1111581



A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD
vilanterol/darotropium bromide
DB1111581
NCT00749411
Pulmonary Disease, Chronic Obstructive
Phase 2
 
May 2013